Emily has more than five years of experience in vaccine development and emerging infectious disease research. She is certified in both Public Health Emergency Preparedness and Vaccine Science and Policy.
At Rabin Martin, she specializes in:
- Developing public health solutions with an emphasis on data-driven approaches
- Designing innovative strategies for stakeholder engagement in public-private partnerships
- Analyzing global health trends to improve access to vaccines in resource-limited settings
Before joining the firm, Emily worked to develop rapid-to-market vaccines for H5N1 and Ebola. She served on several red team exercise panels with the Johns Hopkins Center for Health Security and provided expertise on the impact of new molecular technologies for biodefense. In her work at the International Vaccines Access Center, Emily evaluated global effectiveness of the pneumococcal conjugate vaccine to inform Gavi decision-making. Most recently, as part of her master’s thesis, Emily developed a novel influenza reporter virus to visualize real-time infection and support influenza pandemic preparedness efforts.
ScM, Molecular Microbiology & Immunology
Johns Hopkins Bloomberg School of Public Health
BA, International Studies
BS, Molecular Biology
University of Denver